Analysis of linkage between lymphotoxin α haplotype and polymorphisms in 5′-flanking region of tumor necrosis factor α gene associated with efficacy of infliximab for Crohn's disease patients

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 602, Issue 1-2, 2006, Pages 170-174

  Ozeki, Takeshi ^a   Furuya, Yoko ^a   Nagano, Chieko ^a   Matsui, Chika ^a   Takayanagi, Risa ^a   Yokoyama, Haruko ^a   Yamada, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Crohn's disease; Haplotype analysis; Infliximab; Lymphotoxin ; Tumor necrosis factor

Indexed keywords

CYSTEINE; DNA; GLYCINE; INFLIXIMAB; LYMPHOTOXIN; THREONINE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DNA FLANKING REGION; DRUG EFFICACY; DRUG RESPONSE; GENE INDUCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY EFFECT; TREATMENT RESPONSE;

5' FLANKING REGION; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE (GENETICS); LYMPHOTOXIN-ALPHA; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750622795     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2006.09.002     Document Type: Article

References (16)

1. Garnett W.R., and Yunker N. Treatment of Crohn's disease with infliximab. Am. J. Health Syst. Pharm. 58 (2001) 307-316
2. Sategna-Guidetti C., Pulitano R., Fenoglio L., Bologna E., Manes M., and Camussi G. Tumor necrosis factor/cachectin in Crohn's disease. Relation of serum concentration to disease activity. Recent. Prog. Med. 84 (1993) 93-99
3. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7 (1995) 251-259
4. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J., and Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 337 (1997) 1029-1035
5. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., and Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
6. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Van Hogezand R.A., Braakman T., DeWoody K.L., Schaible T.F., and Van Deventer S.J. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
7. Higuchi T., Seki N., Kamizono S., Yamada A., Kimura A., Kato H., and Itoh K. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese. Tissue Antigens 51 (1998) 605-612
8. Wilson A.G., di Giovine F.S., Blakemore A.I., and Duff G.W. Single base polymorphism in the human tumour necrosis factor α (TNFα) gene detectable by NcoI restriction of PCR product. Hum. Mol. Genet. 1 (1992) 353
9. D'Alfonso S., and Richiardi P.M. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 39 (1994) 150-154
10. Hohjoh H., and Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun. 2 (2001) 105-109
11. Plevy S.E., Targan S.R., Yang H., Fernandez D., Rotter J.I., and Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 110 (1996) 1053-1060
12. Louis E., Vermeire S., Rutgeerts P., Vos M.D., Van Gossum A., Pescatore P., Fiasse R., Pelckmans P., Reynaert H., D'Haens G., Malaise M., and Belaiche J. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37 (2002) 818-824
13. Taylor K.D., Plevy S.E., Yang H., Landers C.J., Barry M.J., Rotter J.I., and Targan S.R. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120 (2001) 1347-1355
14. Kamatani N., Kawamoto M., Kitamura Y., Harigai M., Okumoto T., and Sumio Y. Establishment of B-cell lines derived from 996 Japanese individuals. Tissue Cult. Res. Commun. 23 (2004) 71-80
15. Niu T., Qin Z.S., Xu X., and Liu J.S. Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am. J. Hum. Genet. 70 (2002) 157-169
16. Y. Akiyama, TFSEARCH: Searching Transcription Factor Binding Sites (ver 1.3), http://mbs.cbrc.jp/research/db/TFSEARCHJ.html.